Table 63: Study profiles of included studies on diagnostic accuracy of HbA1c testing for diagnosing diabetes in people with CVD Study and Diagnostic Study Inclusion/exclusion HbA1c HbA1c Reference Reference Outcomes location level of population criteria cut-off— standard standard Quality evidence and diabetes (FPG (FPG assessment study design and/or OGT and/or OGT test)—diabetes Doerr () Level III-2 Low risk of bias. N=1,015 Included patients 5.7–6.4% ≥6.5% IGT: FPG Sensitivity, Germany patients; 69% 54 years of age or older ≥126 mg/dL specificity Study of test No applicability FPG <126 mg/dL male. admitted for acute and/or OGT test accuracy concerns. and OGT test (n=146) or elective ≥200 mg/dL against Mean age ≥140 mg/dL; (n=866) coronary 68.2 ± 9.0 years. IFG: angiography. reference FPG ≥100 mg/dL standard. Excluded patients with and <126 mg/dL known diabetes or history of taking glucose-lowering agents, or with pancreatic, hepatic or kidney disease, or presence of endocrine diseases or treatment with steroid medication. Gianchandani () Level III-2 Low risk of bias. N=92/116 Included patients 5.7–6.4% ≥6.5% IFG: FPG Sensitivity/ patients (12 participating in ongoing ≥126 mg/dL specificity Unites States Study of test No applicability FPG excluded to study following and/or OGT test (2x2) accuracy concerns. mg/dL; rescheduled cardiothoracic surgery ≥200 mg/dL against IGT: surgery, 10 procedures. OGT test declined, 1 reference Excluded patients with mg/dL withdrew, 1 did standard. history of diabetes or of not meet taking medication that criteria). interferes with glucose Mean age metabolism years. (glucocorticoids, immunosuppressive
Table 63: Study profiles of included studies on diagnostic accuracy of HbA1c testing for diagnosing diabetes in people with CVD Study and location Diagnostic level of evidence and study design Quality assessment Study population Inclusion/exclusion criteria HbA1c HbA1c cut-off— diabetes Reference standard (FPG and/or OGT Reference standard (FPG and/or OGT test)—diabetes Outcomes Doerr () Germany Level III-2 Study of test accuracy against reference standard. Low risk of bias. No applicability concerns. N=1,015 patients; 69% male. Mean age 68.2 ± 9.0 years. Included patients 54 years of age or older admitted for acute (n=146) or elective (n=866) coronary angiography. Excluded patients with known diabetes or history of taking glucose-lowering agents, or with pancreatic, hepatic or kidney disease, or presence of endocrine diseases or treatment with steroid medication. 5.7–6.4% ≥6.5% IGT: FPG <126 mg/dL and OGT test ≥140 mg/dL; IFG: FPG ≥100 mg/dL and <126 mg/dL FPG ≥126 mg/dL and/or OGT test ≥200 mg/dL Sensitivity, specificity Gianchandani () Unites States Level III-2 Study of test accuracy against reference standard. Low risk of bias. No applicability concerns. N=92/116 patients (12 excluded to rescheduled surgery, 10 declined, 1 withdrew, 1 did not meet criteria). Mean age years. Included patients participating in ongoing study following cardiothoracic surgery procedures. Excluded patients with history of diabetes or of taking medication that interferes with glucose metabolism (glucocorticoids, immunosuppressive 5.7–6.4% ≥6.5% IFG: FPG mg/dL; IGT: OGT test mg/dL FPG ≥126 mg/dL and/or OGT test ≥200 mg/dL Sensitivity/ specificity (2x2)
1267-FinalContractedAssessmentReport-accessible.DOCX